CN103071154A - 用起因子xa抑制剂作用的化合物的组合抗凝治疗 - Google Patents

用起因子xa抑制剂作用的化合物的组合抗凝治疗 Download PDF

Info

Publication number
CN103071154A
CN103071154A CN2012105706089A CN201210570608A CN103071154A CN 103071154 A CN103071154 A CN 103071154A CN 2012105706089 A CN2012105706089 A CN 2012105706089A CN 201210570608 A CN201210570608 A CN 201210570608A CN 103071154 A CN103071154 A CN 103071154A
Authority
CN
China
Prior art keywords
compd
agent
anticoagulant
acid
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012105706089A
Other languages
English (en)
Chinese (zh)
Inventor
U.辛哈
S.J.霍伦巴赫
P.安德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOUSAND YEARS MEDICAMENTS Inc
Millennium Pharmaceuticals Inc
Original Assignee
THOUSAND YEARS MEDICAMENTS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THOUSAND YEARS MEDICAMENTS Inc filed Critical THOUSAND YEARS MEDICAMENTS Inc
Publication of CN103071154A publication Critical patent/CN103071154A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
CN2012105706089A 2007-04-13 2008-04-11 用起因子xa抑制剂作用的化合物的组合抗凝治疗 Pending CN103071154A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91185207P 2007-04-13 2007-04-13
US60/911852 2007-04-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880019506XA Division CN101743001B (zh) 2007-04-13 2008-04-11 用起因子xa抑制剂作用的化合物的组合抗凝治疗

Publications (1)

Publication Number Publication Date
CN103071154A true CN103071154A (zh) 2013-05-01

Family

ID=39638994

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012105706089A Pending CN103071154A (zh) 2007-04-13 2008-04-11 用起因子xa抑制剂作用的化合物的组合抗凝治疗
CN200880019506XA Expired - Fee Related CN101743001B (zh) 2007-04-13 2008-04-11 用起因子xa抑制剂作用的化合物的组合抗凝治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880019506XA Expired - Fee Related CN101743001B (zh) 2007-04-13 2008-04-11 用起因子xa抑制剂作用的化合物的组合抗凝治疗

Country Status (16)

Country Link
US (3) US20080254036A1 (https=)
EP (2) EP2155195B1 (https=)
JP (2) JP5469595B2 (https=)
KR (1) KR101473207B1 (https=)
CN (2) CN103071154A (https=)
AU (1) AU2008239659B2 (https=)
BR (1) BRPI0809655B8 (https=)
CA (1) CA2683793C (https=)
DO (1) DOP2009000244A (https=)
EA (1) EA020531B1 (https=)
GT (1) GT200900260A (https=)
IL (1) IL201433A (https=)
MX (1) MX2009010953A (https=)
NZ (1) NZ580162A (https=)
TN (1) TN2009000408A1 (https=)
WO (1) WO2008127682A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
KR101195801B1 (ko) 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US20090186810A1 (en) * 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
NZ572418A (en) * 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
CN101595092B (zh) 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
WO2008086226A2 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
CN102762550B (zh) 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
US8742120B2 (en) * 2009-12-17 2014-06-03 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
AR079491A1 (es) 2009-12-17 2012-02-01 Millennium Pharm Inc Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
EP2633857B1 (en) * 2009-12-23 2015-08-12 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US20120052058A1 (en) * 2010-08-30 2012-03-01 Emory University Methods of managing the blood coagulation and pharmaceutical compositions related thereto
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
WO2015038968A1 (en) * 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
JPWO2016035780A1 (ja) * 2014-09-02 2017-06-15 第一三共株式会社 ステント留置後の血栓・塞栓の形成を抑制するための医薬組成物
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN112888312A (zh) * 2018-08-28 2021-06-01 莫尔豪斯医学院 用于预防或降低短暂性脑缺血发作发病率的组合物及方法
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
EP4070658A1 (de) * 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376515B2 (en) * 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384725A3 (en) 1994-04-26 2007-02-21 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
TR200101498T2 (tr) * 1998-11-27 2001-11-21 Basf Aktiengesellschaft İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2316383T3 (es) * 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
CZ2002959A3 (cs) * 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
US6511973B2 (en) * 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
DE10065475A1 (de) * 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
US20030114371A1 (en) * 2001-02-07 2003-06-19 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
JP2007505142A (ja) * 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
US7022695B2 (en) * 2003-10-09 2006-04-04 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of Factor Xa
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
KR101195801B1 (ko) * 2004-06-18 2012-11-05 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE102004046623A1 (de) * 2004-09-25 2006-03-30 Bayer Healthcare Ag Neue Pyrimidin-Derivate und ihre Verwendung
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
PE20070717A1 (es) * 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
US20090186810A1 (en) 2006-03-27 2009-07-23 Portola Pharmaceuticals, Inc. Potassium channel modulators and platelet procoagulant activity
NZ572418A (en) 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
CN101595092B (zh) * 2006-11-02 2012-02-01 米伦纽姆医药公司 合成因子xa抑制剂的医药盐的方法
KR101472765B1 (ko) * 2006-12-08 2014-12-15 밀레니엄 파머슈티컬스 인코퍼레이티드 경구용 Ｘａ 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Ｘａ 인자 억제제를 사용하는 혈전증의 치료 방법
WO2008086226A2 (en) * 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376515B2 (en) * 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa

Also Published As

Publication number Publication date
US20080254036A1 (en) 2008-10-16
KR101473207B1 (ko) 2014-12-16
EP2155195A2 (en) 2010-02-24
WO2008127682A2 (en) 2008-10-23
CN101743001A (zh) 2010-06-16
CN101743001B (zh) 2013-02-06
US20130315897A1 (en) 2013-11-28
GT200900260A (es) 2011-09-05
IL201433A0 (en) 2010-05-31
BRPI0809655A2 (pt) 2014-10-07
IL201433A (en) 2016-02-29
KR20100016428A (ko) 2010-02-12
CA2683793C (en) 2016-09-20
AU2008239659A1 (en) 2008-10-23
EP2591783A1 (en) 2013-05-15
JP5469595B2 (ja) 2014-04-16
EA020531B1 (ru) 2014-11-28
CA2683793A1 (en) 2008-10-23
BRPI0809655B8 (pt) 2021-05-25
TN2009000408A1 (en) 2011-03-31
HK1141230A1 (en) 2010-11-05
EP2155195B1 (en) 2014-07-16
WO2008127682A3 (en) 2009-05-07
JP2013177459A (ja) 2013-09-09
DOP2009000244A (es) 2010-02-28
US20120046230A1 (en) 2012-02-23
MX2009010953A (es) 2009-10-29
US8455440B2 (en) 2013-06-04
JP2010523679A (ja) 2010-07-15
BRPI0809655B1 (pt) 2019-09-10
AU2008239659B2 (en) 2013-09-05
NZ580162A (en) 2012-10-26
EA200970946A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
CN101743001B (zh) 用起因子xa抑制剂作用的化合物的组合抗凝治疗
US12245999B2 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
JP2010523679A5 (https=)
JP5439363B2 (ja) 血小板ａｄｐ受容体阻害剤として作用する化合物による併用療法
JP2022513919A (ja) 血栓性または血小板塞栓性疾患および／または血栓性または血小板塞栓性合併症の治療および／または予防のための置換オキソピリジン誘導体
WO2020131998A1 (en) Notch inhibitors for the treatment of vascular malformations
NO310596B1 (no) Anvendelse av en forbindelse for fremstilling av et medikament for öking av trombomodulinekspresjon
JP7749679B2 (ja) プラスミン阻害剤、その製造方法およびその適用
US20050124667A1 (en) Oxamide inhibitors of plasminogen activator inhibitor-1
JP2025533524A (ja) ユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤およびｐａｒｐ１特異的阻害剤を含む治療的組合せ
CN104098647A (zh) 阿加曲班类似物及其制备方法和医药用途
HK1141230B (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
JPH01250350A (ja) 循環器用剤
Nagakura Finding of Novel Anti-Thrombotic Drug via Selective Inhibition of Extrinsic Coagulation Pathway
TW202404601A (zh) 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑
EP2505202A1 (en) D-myo-inositol 3,4,5,6-tetrakisphosphate to modulate thrombin/antithrombin activity by heparin binding

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130501